European Commission approves Vaxneuvance (pneumococcal 15-valent conjugate vaccine) for individuals 18 years of age and older – Merck Inc
Merck Inc., announced that the European Commission (EC) has approved Vaxneuvance (Pneumococcal 15-valent Conjugate Vaccine) for active immunization for the prevention of invasive disease and pneumonia caused by… read more.
